Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation

被引:108
作者
Angelucci, E
Muretto, P
Lucarelli, G
Ripalti, M
Baronciani, D
Erer, B
Galimberti, M
Giardini, C
Gaziev, D
Polchi, P
Rovelli, A
Monguzzi, W
Masera, G
Piga, A
Garofalo, F
Gabutti, V
DiGregorio, F
Romeo, MA
Cammella, A
Russo, G
Gallisai, D
Burrai, C
Costi, C
Marinaro, AM
Erbeia, M
Mazzani, D
Nobili, B
Perrotta, S
Ferrara
Cutillo, S
Mulas, G
Careddu, F
Mancini, E
Argiolu, F
Addari, C
Ruggiero, L
DeNunzio, A
Terzoli, S
DAscola, G
Bruciatelli, M
Satta, AM
BorgnaPignatti, C
Marradi, P
Puggioni, G
Murgia, T
Porta, E
Poggi, V
PintaBoccalatte, MF
Polizzi, B
Maroni, P
机构
[1] AZIENDA OSPED PESARO,CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA,I-61100 PESARO,ITALY
[2] AZIENDA OSPED PESARO,SERV ANAT PATOL,PESARO,ITALY
关键词
D O I
10.1182/blood.V90.3.994.994_994_998
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In thalassemia after successful bone marrow transplantation (BMT), iron overload remains an important cause of morbidity, After BMT, patients have normal erythropoiesis capable of producing a hyperplastic response to phlebotomy so that this procedure can be contemplated as a method of mobilizing iron from overloaded tissues. A phlebotomy program (6 mL/kg blood withdrawal at 14-day intervals) was proposed to 48 patients with prolonged follow-up (range, 2 to 7 years) after BMT. Seven patients were not submitted to the program (five because of refusal and two because of reversible side effects). The remaining 41 patients (mean age, 16 +/- 2.9 years) were treated for a mean period of 35 +/- 18 months. All were evaluated before and after 3 +/- 0.6 years of follow-up. Values are expressed as mean +/- standard deviation (SD) or as median with a range (25 to 75 percentile). Serum ferritin decreased from 2,587 (2,129 to 4,817) to 417 (210 to 982) mu g/L (P < .0001), total transferrin increased from 2.34 +/- 0.37 to 2.7 +/- 0.58 g/L (P = .0001), transferrin saturation decreased from 90% +/- 14% to 50% +/- 29% (P < .0001). Liver iron concentration evaluated on liver biopsy specimens decreased from 20.8 (15.5 to 28.1) to 4.2 (1.6 to 14.6) mg/g dry weight (P < .0001). Aspartate transaminase decreased from 2.7 +/- 2 to 1.1 +/- 0.6 (P < .0001) and alanine transaminase from 5.2 +/- 3.4 to 1.7 +/- 1.2 (P < .0001) times the upper level of normality. The Knodell score for liver histological activity decreased from 6.9 +/- 3 to 4.9 +/- 2.8 (P < .0001). These data indicate that phlebotomy is safe, efficient, and widely applicable to ex-thalassemics after BMT. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:994 / 998
页数:5
相关论文
共 29 条
[11]   COMPARATIVE EFFICACY AND TOXICITY OF DESFERRIOXAMINE, DEFERIPRONE AND OTHER IRON AND ALUMINUM CHELATING DRUGS [J].
KONTOGHIORGHES, GJ .
TOXICOLOGY LETTERS, 1995, 80 (1-3) :1-18
[12]  
KONTOGHIORGHES GJ, 1994, LANCET, V343, P604
[13]   LONG-TERM EFFECTS OF HEPATITIS-C VIRUS-INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS [J].
LJUNGMAN, P ;
JOHANSSON, N ;
ASCHAN, J ;
GLAUMANN, H ;
LONNQVIST, B ;
RINGDEN, O ;
SPARRELID, E ;
SONNERBORG, A ;
WINIARSKI, J ;
GAHRTON, G .
BLOOD, 1995, 86 (04) :1614-1618
[14]   MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA RESPONSIVE TO IRON CHELATION-THERAPY [J].
LUCARELLI, G ;
GALIMBERTI, M ;
POLCHI, P ;
ANGELUCCI, E ;
BARONCIANI, D ;
GIARDINI, C ;
ANDREANI, M ;
AGOSTINELLI, F ;
ALBERTINI, F ;
CLIFT, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (12) :840-844
[15]   BONE-MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA [J].
LUCARELLI, G ;
GALIMBERTI, M ;
POLCHI, P ;
ANGELUCCI, E ;
BARONCIANI, D ;
GIARDINI, C ;
POLITI, P ;
DURAZZI, SMT ;
MURETTO, P ;
ALBERTINI, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (07) :417-421
[16]   FATE OF IRON STORES IN THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION [J].
LUCARELLI, G ;
ANGELUCCI, E ;
GIARDINI, C ;
BARONCIANI, D ;
GALIMBERTI, M ;
POLCHI, P ;
BARTOLUCCI, M ;
MURETTO, P ;
ALBERTINI, F .
LANCET, 1993, 342 (8884) :1388-1391
[17]  
MAHARAJ B, 1986, LANCET, V1, P523
[18]  
McKay PJ, 1996, BONE MARROW TRANSPL, V17, P63
[19]  
MURETTO P, 1994, LIVER, V14, P14
[20]   HEPATIC IRON CONCENTRATION AS A PREDICTOR OF RESPONSE TO INTERFERON-ALFA THERAPY IN CHRONIC HEPATITIS-C [J].
OLYNYK, JK ;
REDDY, KR ;
DIBISCEGLIE, AM ;
JEFFERS, LJ ;
PARKER, TI ;
RADICK, JL ;
SCHIFF, ER ;
BACON, BR .
GASTROENTEROLOGY, 1995, 108 (04) :1104-1109